
<?xml version="1.0" encoding="UTF-8"?>
<tiskova_zprava>
    <titulek>
        MHRA Chief Executive update to MHRA staff on the Pathways clinical trial
    </titulek>
    <datum>
        24.3.2026
    </datum>
    <autor>
          | Her Majesty's Revenue and Customs
    </autor>
    <perex>
         As with all clinical trials, the MHRA’s top priority is the safety and wellbeing of the trial participants. 
    </perex>
    <text>
        
Following the update published on 27 February 2026, we are publishing, for transparency, a copy of an email sent to all MHRA staff by Chief Executive Lawrence Tallon on 11 March 2026, regarding the Pathways clinical trial.

A copy of the email is available here: MHRA staff email - 11 March 2026 (PDF, 125 KB, 2 pages)

https://www.gov.uk/government/news/mhra-chief-executive-update-to-mhra-staff-on-the-pathways-clinical-trial


    </text>
</tiskova_zprava>
